Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Phase I/II Clinical Trial of SYS6043 Monotherapy or SYS6043 Combined With PD-1/VEGF Bispecific Antibody ± Chemotherapy in the Treatment of Advanced Solid Tumors.

16 november 2026 uppdaterad av: CSPC Megalith Biopharmaceutical Co.,Ltd.

An Open-label, Multicenter Phase I/II Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SYS6043 Monotherapy or SYS6043 Combined With PD-1/VEGF Bispecific Antibody ± Chemotherapy in Patients With Advanced Solid Tumors.

This is a multicenter phase 1/2 clinical study to evaluate the efficacy and safety of SYS6043 monotherapy or SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy in patients with advanced solid tumors.

Studieöversikt

Detaljerad beskrivning

The Phase I study is a a dose-escalation study, comprises dose escalation for the doublet regimen and dose escalation for the triplet regimen. The Phase II study isa cohort expansion study.

Phase I: the dose escalation use a 3+3 design. The doublet regimen consists of SYS6043 + PD-1/VEGF bispecific antibody. The triplet regimen consists of SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy.

The Phase II study will be conducted as an expansion in 6 cohorts, with indications including triple-negative breast cancer, small cell lung cancer, non-small cell lung cancer, etc.

Studietyp

Interventionell

Inskrivning (Beräknad)

368

Fas

  • Fas 2
  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Be able to understand and voluntarily sign and datethe written ICF prior to any trial-related procedure;
  2. Age 18-75 (inclusive) years;
  3. Histologically or cytologically confirmed advanced/unresectable or metastatic solid tumors(specific cohort requirements apply, including TNBC, SCLC, and driver-gene negative NSCLC based on UICC/AJCC 8th edition staging);
  4. Dose escalation phase: evaluable lesions per RECIST v1.1. Dose expansion phase: at least one extracranial measurable lesion per RECIST v1.1. Lesions previously treated with radiotherapy or other local therapy may not be selected as target lesions unless there is clear evidence of progression.
  5. Qualified archived or fresh tumor tissue samples must be provided; participants who cannot provide tumor samples or whose samples are insufficient may be enrolled based on individual circumstances.
  6. Eastern Cooperative Oncology Group (ECOG) performance status score: 0-1;
  7. Adequate organ and bone marrow function within 7 days prior to the first dose, as defined below.
  8. Life expectancy ≥ 3 months;
  9. Female participants of childbearing age must have a negative serum pregnancy test within 7 days before dosing. Male and female participants of reproductive potential must agree to use adequate contraception during the study and for at least 7 months after the last dose of the investigational product; during this period, female participants must not be breastfeeding, male participants must not freeze or donate sperm, and female participants must not donate eggs or undergo egg retrieval for personal use.

Exclusion Criteria:

  1. Combined SCLC (i.e., mixed large cell carcinoma, squamous cell carcinoma, spindle/pleomorphic and/or large cell components) and transformed SCLC.
  2. Prior history of CTCAE grade ≥3 immune-related adverse events (irAEs) during treatment with anti-PD-(L)1 or other immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy, or other therapies targeting tumor immune mechanisms, except for endocrine disorders such as hyperglycemia or hypothyroidism that have recovered to grade ≤2.
  3. Prior treatment with B7-H3-targeted therapies (including antibodies, antibody-drug conjugates [ADCs], chimeric antigen receptor T-cell [CAR-T] therapies, and other agents).
  4. Prior treatment with a topoisomerase I inhibitor antibody-drug conjugate or a topoisomerase I inhibitor.
  5. Toxicities from prior antitumor therapy have not resolved to CTCAE grade ≤1 or to the levels specified in the inclusion/exclusion criteria (except alopecia and hyperpigmentation).
  6. History of underlying pulmonary disease, including but not limited to severe asthma, severe COPD, restrictive lung disease, and other clinically significant pulmonary impairment or requirement for supplemental oxygen.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: SYS6043+PD-1/VEGF bispecific antibody

SYS6043: IV PD-1/VEGF bispecific antibody: IV

Experimentell: SYS6043 combined with PD-1/VEGF bispecific antibody +chemotherapy.

SYS6043: IV PD-1/VEGF bispecific antibody: IV Chemotherapy: cisplatin or carboplatin, IV

Experimentell: SYS6043 monotherapy

SYS6043: IV

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Phase I: Incidences of AEs
Tidsram: From the signing of the informed consent form until 90 days after the last dose.
From the signing of the informed consent form until 90 days after the last dose.
Phase I: DLT
Tidsram: 21 days

Dose-limiting toxicity

21 days
Phase I: MTD/RP2D
Tidsram: After phase I dose escalation stage. Approximately 4 months.

Maximum Tolerated Dose/ Recommended Phase II Dose

After phase I dose escalation stage. Approximately 4 months.
Phase II: ORR
Tidsram: Up to 2 years

Objective response rate

Up to 2 years

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Phase I: ORR
Tidsram: Up to 2 years

Objective response rate

Up to 2 years
Phase I:DCR
Tidsram: Up to 2 years

Disease control rate

Up to 2 years
Phase I:DOR
Tidsram: Up to 2 years

Duration of response

Up to 2 years
Phase I: TTR
Tidsram: Up to 2 years

Time to Response

Up to 2 years
Phase I: PFS
Tidsram: Up to 2 years

Progression free survival

Up to 2 years
Phase I:OS
Tidsram: Up to 3 years

Overall survival

Up to 3 years
Phase I:Plasma concentrations of SYS6043, total antibody, and free JS-1.
Tidsram: Up to 2 years
Up to 2 years
Phase I:Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) for SYS6043.
Tidsram: Up to 2 years
Up to 2 years
Phase I:Expression levels of proteins such as B7-H3 and PD-L1 in tumor tissue.
Tidsram: Up to 2 years
Up to 2 years
Phase II:DCR
Tidsram: Up to 2 years

Disease control rate

Up to 2 years
Phase II:DOR
Tidsram: Up to 2 years

Duration of response

Up to 2 years
Phase II: TTR
Tidsram: Up to 2 years

Time to Response

Up to 2 years
Phase II: PFS
Tidsram: Up to 2 years

Progression free survival

Up to 2 years
Phase II:OS
Tidsram: Up to 3 years
Up to 3 years
Title: Phase II: Incidences of AEs
Tidsram: From the signing of the informed consent form until 90 days after the last dose.

Overall survival

From the signing of the informed consent form until 90 days after the last dose.
Phase II:Plasma concentrations of SYS6043, total antibody, and free JS-1.
Tidsram: Up to 2 years
Up to 2 years
Phase II:Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) for SYS6043.
Tidsram: Up to 2 years
Up to 2 years
Phase II:Expression levels of proteins such as B7-H3 and PD-L1 in tumor tissue.
Tidsram: Up to 2 years
Up to 2 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

30 december 2026

Primärt slutförande (Beräknad)

30 december 2028

Avslutad studie (Beräknad)

30 december 2029

Studieregistreringsdatum

Först inskickad

13 november 2026

Först inskickad som uppfyllde QC-kriterierna

16 november 2026

Första postat (Faktisk)

20 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

20 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • SYS6043-005

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera